Business Context and Reporting Period
This Form 8-K Current Report was filed by TriSalus Life Sciences, Inc. on August 29, 2025, covering events occurring on August 25, 2025. The registrant is an emerging growth company incorporated in Delaware, with its principal executive office in Westminster, Colorado. The filing primarily addresses Item 5.02 regarding changes in executive compensation.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The only financial figures disclosed relate to executive compensation adjustments:
- CFO Base Salary Increase: Raised from $450,000 to $550,000 annually.
- Stock Option Grant: 249,899 options granted with an exercise price of $5.11 per share.
Material Changes
The material change reported is the adjustment to the Chief Financial Officer's (Mr. David Patience) compensatory arrangements, approved by the Compensation Committee:
- Salary Adjustment: Effective immediately on August 25, 2025, the annual base salary was increased by $100,000.
- Equity Incentive: On August 28, 2025, stock options were granted contingent upon performance milestones.
Guidance, Outlook, and Risks
The filing outlines a specific performance-based vesting condition for the newly granted stock options, which serves as a proxy for management's revenue outlook:
- Performance Milestone: Options vest only if the Company achieves or exceeds $75 million in revenue over any twelve (12) consecutive calendar month period ending on or before December 31, 2027.
- Risk/Contingency: The value of the equity grant is contingent on meeting this specific revenue target; failure to achieve the milestone results in the options not vesting.
Investor Verification Checklist
- Verify the current revenue trajectory to assess the feasibility of the $75 million annual revenue target required for option vesting.
- Review the Executive Employment Agreement dated May 27, 2025, to understand the original compensation structure prior to this increase.
- Confirm the total number of outstanding shares and the potential dilution impact of the 249,899 new options if vested.
- Monitor future filings for updates on the Company's progress toward the December 31, 2027, revenue milestone.